Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression

This post hoc analysis assessed the benefit–risk profile of esketamine nasal spray + oral antidepressant (AD) induction and maintenance treatment in patients with treatment‐resistant depression (TRD). The Benefit–Risk Action Team framework was utilized to assess the benefit–risk profile using data f...

Descripción completa

Detalles Bibliográficos
Autores principales: Katz, Eva G., Hough, David, Doherty, Teodora, Lane, Rosanne, Singh, Jaskaran, Levitan, Bennett
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894501/
https://www.ncbi.nlm.nih.gov/pubmed/32860422
http://dx.doi.org/10.1002/cpt.2024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894501/
https://www.ncbi.nlm.nih.gov/pubmed/32860422
http://dx.doi.org/10.1002/cpt.2024

Ejemplares similares